In its second respiratory deal in two days, drugmaker Lupin Ltd has launched an inhalation-drug delivery device InspiraChamber under a licensing agreement with New Jersey-based respiratory research and development company InspiRX Inc.
Developed by InspiRX, the InspiraChamber ® anti-static valved holding chamber is a device that has been designed to enhance delivery of aerosol therapies. And the agreement grants Lupin exclusive rights to promote, distribute and market InspiraChamber in the US.
Valved holding chambers make it easier for young children and the elderly to take their asthma medicines. Depending on the treatment type, asthma medicines could either be for quick-relief/rescue or long-term control and they are administered via pressurised metered-dose inhalers, the company explained.